Zydus announces IND clearance of a novel Anti-PCSK9 candidate, aiming to treat Dyslipidemia with a once-in-6-month dosing regimen through Phase 1 clinical trials.
AI Assistant
Zydus Lifesciences Ltd
2023
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.